The DNA damage response, immunity and cancer

Seminars in Cancer Biology

Volumn 16, Issue 5, 2006, Pages 344-347

  Gasser, Stephan ^a   Raulet, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; DNA damage; Tumor surveillance

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN P53;

APOPTOSIS; CANCER; CARCINOGENESIS; CELL ACTIVATION; CELL CYCLE ARREST; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; IMMUNOSURVEILLANCE; MULTIGENE FAMILY; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR IMMUNITY;

ANIMALS; DNA DAMAGE; DNA REPAIR; HUMANS; IMMUNITY, CELLULAR; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC; RECEPTORS, NATURAL KILLER CELL;

EID: 33748207131     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2006.07.004     Document Type: Review

References (22)

1. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
2. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
3. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005) 1186-1190
4. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73 (2004) 39-85
5. Ishikawa T., Zhang S.S., Qin X., Takahashi Y., Oda H., Nakatsuru Y., et al. DNA repair and cancer: lessons from mutant mouse models. Cancer Sci 95 (2004) 112-117
6. Attardi L.D. The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat Res 569 (2005) 145-157
7. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3 (2003) 781-790
8. Jamieson A.M., Diefenbach A., McMahon C.W., Xiong N., Carlyle J.R., and Raulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17 (2002) 19-29
9. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., and Raulet D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1 (2000) 119-126
10. Diefenbach A., Jensen E.R., Jamieson A.M., and Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001) 165-171
11. Cerwenka A., Bakker A.B., McClanahan T., Wagner J., Wu J., Phillips J.H., et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12 (2000) 721-727
12. Westwood J.A., Kelly J.M., Tanner J.E., Kershaw M.H., Smyth M.J., and Hayakawa Y. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4 + T cell pathway. J Immunol 172 (2004) 757-761
13. Zhou H., Luo Y., Lo J.F., Kaplan C.D., Mizutani M., Mizutani N., et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci USA 102 (2005) 10846-10851
14. Oppenheim D.E., Roberts S.J., Clarke S.L., Filler R., Lewis J.M., Tigelaar R.E., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6 (2005) 928-937
15. Smyth M.J., Swann J., Cretney E., Zerafa N., Yokoyama W.M., and Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 202 (2005) 583-588
16. Waldhauer I., and Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66 (2006) 2520-2526
17. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
18. DiTullio Jr. R.A., Mochan T.A., Venere M., Bartkova J., Sehested M., Bartek J., et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 4 (2002) 998-1002
19. Wallace-Brodeur R.R., and Lowe S.W. Clinical implications of p53 mutations. Cell Mol Life Sci 55 (1999) 64-75
20. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
21. Zagozdzon R., and Golab J. Immunomodulation by anticancer chemotherapy: more is not always better. Int J Oncol 18 (2001) 417-424 [review]
22. DiPaola R.S., Durivage H.J., and Kamen B.A. High time for low-dose prospective clinical trials. Cancer 98 (2003) 1559-1561